126052-34-4

Usage

Uses

Used in Medicinal Chemistry and Drug Discovery:
3-Phenylimidazo[1,2-a]pyrazine is utilized as a potential anti-cancer agent, given its unique structure that may contribute to the development of new pharmaceutical compounds targeting various types of cancer.
Used in Fluorescent Probe Development:
In the field of analytical chemistry, 3-Phenylimidazo[1,2-a]pyrazine is explored as a fluorescent probe for the detection of metal ions in biological systems, capitalizing on its ability to emit fluorescence upon interaction with specific ions.
Further research is essential to fully elucidate the properties and potential applications of 3-Phenylimidazo[1,2-a]pyrazine, ensuring its safe and effective use in various industries.

InChI:InChI=1/C12H9N3/c1-2-4-10(5-3-1)11-9-15-7-6-13-8-12(15)14-11/h1-9H

Upstream product

• 1447607-84-2 8-chloro-2-phenylimidazo[1,2-a]pyrazine 
• 98-86-2 acetophenone 
• 5049-61-6 2-Aminopyrazine 
• 98-80-6 phenylboronic acid 
• 70-11-1 α-bromoacetophenone 

Downstream Products

• 1254709-40-4 3-bromo-2-phenylimidazo[1,2-a]pyrazine 

Relevant academic research and scientific papers

Synthesis, antileishmanial activity and cytotoxicity of 2,3-diaryl- and 2,3,8-trisubstituted imidazo[1,2-a]pyrazines

A series of original 2-phenyl-3-(pyridin-4-yl)imidazo[1,2-a]pyrazines and the 3-iodo precursors, bearing a polar moiety at the C-8 position, was synthesized and evaluated for their antileishmanial activities. Two derivatives exhibited very good activity a

One-pot synthesis of 6H-2,2a1,3-triazaaceanthrylen-6-ones and 6H-2,2a1,4-triazaaceanthrylen-6-ones via tandem cyclization strategies

Two operationally simple one-pot protocols have been developed for the synthesis of 6H-2,2a1,3-triazaaceanthrylen-6-ones and 6H-2,2a1,4-triazaaceanthrylen-6-ones. The first Pd-catalyzed tandem cyclization of imidazo[1,2-a]pyrimidines/imidazo[1,2-a]pyrazines with 2-chlorobenzaldehydes could proceed in aqueous medium under air, affording the desired products in moderate to good yields. The molecular structures of products 3i and 5b were confirmed by X-ray crystallographic analysis.

IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, [Formula should be inserted here] Also provided herein are pharmaceutical compositions, comprising compounds of Formula (I), and methods of

General Method for the Preparation of Electron-Deficient Imidazo[1,2-a]pyridines and Related Heterocycles

A new annulation method for the preparation of the imidazo[1,2-a]pyridine ring system under mild conditions is presented. Treatment of a 2-aminopyridine with a dimethylketal tosylate in acetonitrile at elevated temperature (80-140°C) in the presence of catalytic Sc(OTf)3 provides the imidazo[1,2-a]pyridine product in good yield. The annulation method is broadly applicable to electron-poor 2-aminopyridines and displays a complementary profile to the classic preparation of the imidazo[1,2-a]pyridine ring system by reaction of a bromoketone with electron-rich and -neutral substrates. The scope of the process and mechanistic considerations are discussed.

Structure activity relationship studies of imidazo[1,2-a]pyrazine derivatives against cancer cell lines

Designed novel imidazo[1,2-a]pyrazine based inhibitors, synthesized by condensing α-aminopyrazines with α-halocarbonyl compounds followed by electrophilic substitutions. Cytotoxic effects on four cancer cell lines evaluated. Based on preliminary data, imidazo[1,2-a]pyrazine template redesigned to improve activity.